We are grateful for the 2020 VDS Meeting Sponsors
Pamela Hamacher | email@example.com
Kevin Feese | firstname.lastname@example.org
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
Parker McKoy | Otezla Sales Specialist
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Castle Biosciences, Inc. | Area Manager VA/WV
Cell: 757-303-4465 | email@example.com
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (https://castletestinfo.com).
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions on the risk of sentinel lymph node positivity and the intensity of follow-up, surveillance imaging, referral and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and sentinel lymph node status and is supported by consistent evidence in over 25 publications including two meta-analyses showing Level 1A evidence classification.
Newly available DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
Castle Biosciences has ongoing development programs in other underserved dermatologic cancers. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona.
o Castle Biosciences Website - http://castlebiosciences.com/
o Castle Test Info - https://castletestinfo.com/
o Order a Castle Biosciences Test - https://clabsportal.com:8450/castle_portal/
Megan Duke – 804-839-1292 MDuke2@Its.jnj.com
Renee Thomas – 757-636-6325 - RThomas10@its.jnj.com
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com.
Follow us at www.twitter.com/JanssenGlobal.
Rebekah Dennison | Client Services Representative
Lab: 434-244-0162, option 2 | Cell: 434-422-0890
David M. Rowe, MD
Now in our 10th year of practice, PRW Laboratories is a CAP-accredited, independent, stand-alone, full-service, dermatopathology laboratory located in Charlottesville, VA. Our team of board-certified dermatopathologists (with backgrounds in dermatology and surgical pathology) work together for “concierge-level dermatopathology” with an emphasis on turnaround time, communication, and expert diagnosis. We serve a region of central and western Virginia reaching from Richmond to Staunton (E-W) and Harrisonburg to Radford (N-S). Some of our experts are the authors of leading textbooks and numerous journal articles and serve as consultants for second opinion cases statewide and nationally. Beyond diagnostic services, PRW is an educational resource for two regional dermatology residencies.
Paul Hankey | Paul.Hankey@sanofi.com
Meredith Luck | Meredith.Luck@sanofi.com
See What’s Possible with DUPIXENT® (dupilumab).
DUPIXENT® is a registered trademark of Sanofi Biotechnology.
©2020 Sanoﬁ and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
Stephanie Mebane, Area Business Manager
Gary McDaniel, Medical Account Specialist
Since 2007, Regeneron and Sanofi have collaborated to help people with debilitating and complex conditions that are often difficult to diagnose and treat, using fully-human monoclonal antibodies. Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology.
© 2020 Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. All rights reserved.
Sallie Cooke | Sr Clinical Account Specialist
Sallie.firstname.lastname@example.org | 757-291-6200
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases of the immune system and the central nervous system. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of more than 8,500 employees and operations in 40 countries, we are a global biopharmaceutical company investing nearly 25% of revenue in cutting-edge scientific research to meet unmet patient needs. The company is based in Brussels, Belgium, with U.S. headquarters located in Atlanta, Georgia.